Hsbc Holdings PLC Decreases Holdings in Cencora, Inc. (NYSE:COR)

Hsbc Holdings PLC decreased its position in shares of Cencora, Inc. (NYSE:COR - Free Report) by 8.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 386,827 shares of the company's stock after selling 35,240 shares during the period. Hsbc Holdings PLC owned approximately 0.20% of Cencora worth $86,924,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Passumpsic Savings Bank boosted its holdings in Cencora by 4.9% in the 3rd quarter. Passumpsic Savings Bank now owns 6,464 shares of the company's stock valued at $1,455,000 after purchasing an additional 304 shares during the period. Virtu Financial LLC boosted its stake in shares of Cencora by 112.2% in the third quarter. Virtu Financial LLC now owns 10,227 shares of the company's stock valued at $2,302,000 after buying an additional 5,407 shares during the period. World Investment Advisors LLC bought a new stake in shares of Cencora in the third quarter valued at approximately $4,072,000. Arvest Bank Trust Division acquired a new stake in Cencora during the third quarter worth approximately $218,000. Finally, Wilmington Savings Fund Society FSB bought a new position in Cencora during the 3rd quarter worth $566,000. Institutional investors and hedge funds own 97.52% of the company's stock.

Insider Activity

In other Cencora news, Chairman Steven H. Collis sold 14,579 shares of the firm's stock in a transaction that occurred on Tuesday, April 22nd. The stock was sold at an average price of $281.81, for a total value of $4,108,507.99. Following the completion of the sale, the chairman now owns 315,913 shares of the company's stock, valued at approximately $89,027,442.53. This trade represents a 4.41 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CAO Lazarus Krikorian sold 2,000 shares of the company's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $260.06, for a total transaction of $520,120.00. Following the transaction, the chief accounting officer now owns 20,154 shares in the company, valued at approximately $5,241,249.24. The trade was a 9.03 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 50,223 shares of company stock worth $13,580,967 in the last quarter. 10.80% of the stock is owned by corporate insiders.

Cencora Trading Up 0.1 %

Shares of NYSE:COR traded up $0.25 during midday trading on Tuesday, hitting $288.00. 299,802 shares of the stock were exchanged, compared to its average volume of 1,517,312. The business's 50-day moving average price is $268.94 and its 200 day moving average price is $250.00. Cencora, Inc. has a 12 month low of $214.77 and a 12 month high of $296.65. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. The stock has a market capitalization of $55.85 billion, a price-to-earnings ratio of 40.99, a P/E/G ratio of 1.31 and a beta of 0.55.

Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, beating analysts' consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were given a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 0.76%. The ex-dividend date was Friday, February 14th. Cencora's dividend payout ratio (DPR) is 31.29%.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on COR. JPMorgan Chase & Co. increased their target price on Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a report on Friday, January 24th. Bank of America raised their target price on shares of Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a report on Friday, April 11th. StockNews.com upgraded shares of Cencora from a "hold" rating to a "buy" rating in a research report on Wednesday, March 12th. Evercore ISI lifted their price objective on shares of Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a research note on Thursday, February 6th. Finally, Morgan Stanley set a $288.00 target price on Cencora in a research note on Tuesday, April 15th. Two investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat.com, Cencora presently has a consensus rating of "Moderate Buy" and a consensus price target of $289.09.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.